Baby powder Johnson & Johnson causes cancer

• Baby powder Johnson & Johnson of causing cancer

California court ordered the company Johnson & Johnson to pay a record $ 417 million dollars a resident of Los Angeles. 65-year-old Eva Echeverria said that the cause of her illness was the baby powder with talcum Johnson's Baby Powder, which she has used for 11 years for personal hygiene.

Baby powder Johnson & Johnson causes cancer Baby powder Johnson & Johnson causes cancer

A resident of California sued Johnson & Johnson a record 417 million dollars as compensation for cancers induced by the use of the company's products. Los Angeles court ruled that the company must pay $ 68 million as compensation for non-pecuniary damage and another 340 million in the form of a penalty.

Baby powder Johnson & Johnson causes cancer

The lawsuit on the company Eva Echeverria filed due to the development of ovarian cancer after use of talc. She enjoyed baby powder on a daily basis from 1950 to 2016, in 2007 she was diagnosed with ovarian cancer. According to women, the company failed to warn consumers about the risk of developing the disease. The complainant stated that her illness was the result of "unreasonably dangerous and defective nature of talc." Company officials said they will challenge the decision of the court, arguing that science has proven the safety of baby talc from Johnson.

Baby powder Johnson & Johnson causes cancer

The awarding of a resident of California, the sum of 417 million dollars was a record among the compensations, which the company J & J ever paid by the court. It is worth noting that a similar lawsuit against the company is not the only one. Total in US courts of different instances are pending several thousand such appeals.

Baby powder Johnson & Johnson causes cancer

In May 2017 a court in Virginia ordered Johnson & Johnson to pay 110, $ 5 million women using powder that company diseased and ovarian cancer, and the three plaintiffs from St. Louis to sue corporations for a total of over $ 300 million.